PerCP/Cyanine5.5 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_PerCPCyanine55_CD8a_Antibody_102318
C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD8a (clone 53-6.7) PerCP/Cyanine5.5, or Rat IgG2a, κ PerCP/Cyanine5.5 isotype control (bottom).
  • 53-6dot7_PerCPCyanine55_CD8a_Antibody_102318
    C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD8a (clone 53-6.7) PerCP/Cyanine5.5, or Rat IgG2a, κ PerCP/Cyanine5.5 isotype control (bottom).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
100733 25 µg 71€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100734 100 µg 194€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/mL
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is < 1.0 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes

BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Dekhtiarenko I, et al. 2013. J Immunol. 190:3399. PubMed
  2. Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed
  3. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  4. White C, et al. 2015. J Immunol. 194:697. PubMed
  5. Mizraji* G, et al. 2013. J Vis Exp. 77: 50388. PubMed
  6. MaruYama T, et al. 2015. J Leukoc Biol. 98: 385-393. PubMed
  7. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  8. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  9. JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed
  10. Pilzecker B, et al. 2016. Nucleic Acids Res. 44: 4734 - 4744. PubMed
  11. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  12. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed
  13. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  14. Gorman M, et al. 2016. J Virol. 90: 8212 - 8225. PubMed
  15. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
  16. Chandra J, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.83. PubMed
  17. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  18. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  19. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
  20. Younes AI, et al. 2021. Transl Oncol. 14:100983. PubMed
  21. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  22. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  23. Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
  24. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  25. Chen L, et al. 2020. Cancer Immunol Res. 0.457638889. PubMed
  26. Dai L, et al. 2020. Cell. 182(3):722-733.e11. PubMed
  27. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
  28. Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed
  29. Cornax I, et al. 2021. Microorganisms. 9:00. PubMed
  30. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
  31. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  32. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  33. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  34. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  35. Platt DJ, et al. 2021. Cell Reports. 35(6):109113. PubMed
  36. Okada R, et al. 2021. EBioMedicine. 67:103345. PubMed
  37. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  38. Sheppard S, et al. 2021. Cell Reports. 35(9):109210. PubMed
  39. Borkner L, et al. 2017. J Immunol. 10.4049/jimmunol.1602115. PubMed
  40. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
  41. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  42. Chung L et al. 2018. Cell host & microbe. 23(2):203-214 . PubMed
  43. Solanki A, et al. 2018. Development. 145. PubMed
  44. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  45. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  46. Xu J et al. 2018. Cell. 173(3):762-775 . PubMed
  47. Lee SC et al. 2018. Cancer cell. 34(2):225-241 . PubMed
  48. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  49. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  50. Wang Z et al. 2018. Immunity. 49(1):80-92 . PubMed
  51. Kooreman NG et al. 2018. Cell stem cell. 22(4):501-513 . PubMed
  52. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  53. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  54. Shi R, et al. 2019. J Cancer. 10:367. PubMed
  55. Novince CM, et al. 2017. Sci Rep. 7:5747. PubMed
  56. Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed
  57. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  58. Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed
  59. Karandikar SH, et al. 2019. Anal Chem. 91:3405. PubMed
  60. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  61. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  62. Karandikar SH, et al. 2019. JCI Insight. 5. PubMed
  63. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  64. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
  65. Bennion BG, et al. 2019. J Virol. 93. PubMed
  66. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  67. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  68. Highton AJ, et al. 2019. Wellcome Open Res. 4:78. PubMed
  69. Li A, et al. 2018. Cancer Lett. 431:54. PubMed
  70. Zhang P et al. 2019. Cell Rep. 27(11):3117-3123 . PubMed
  71. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  72. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  73. Tang Y, et al. 2019. Nat Commun. 10:4157. PubMed
  74. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  75. Green DP, et al. 2019. Neuron. 101:412. PubMed
  76. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  77. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  78. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  79. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  80. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
  81. Yoon J et al. 2018. J Vis Exp. -141 . PubMed
  82. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  83. Turecamo SE, et al. 2018. Matrix Biol. 67:01:00. PubMed
  84. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  85. Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed
  86. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
  87. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  88. Wolf Y, et al. 2019. Cell. 179:219. PubMed
  89. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  90. Strattan E, et al. 2020. Frontiers in Immunology. 2.131944444. PubMed
  91. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  92. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  93. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  94. Kaur A, et al. 2019. Cancer Discov. 9:64. PubMed
  95. Lang J, et al. 2020. Nat Commun. 11:1338. PubMed
  96. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  97. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  98. Kunishita Y, et al. 2020. Front Immunol. 11:98. PubMed
  99. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  100. Ren J, et al. 2019. PLoS Biol. 17:e3000270. PubMed
  101. Aldon Y, et al. 2020. J Immunol. 204:903. PubMed
  102. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  103. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  104. Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed
  105. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  106. Cohen MA, et al. 2020. Cell Stem Cell. 26(4):579-592. PubMed
  107. Hong JY, et al. 2020. Cell. 180(5):847-861. PubMed
  108. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  109. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  110. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
RRID
AB_2075239 (BioLegend Cat. No. 100733)
AB_2075238 (BioLegend Cat. No. 100734)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC, IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC, CyTOF®, IHC-F, IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC, 3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC, IHC-F, 3D IHC, SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC, IHC, SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC, CyTOF®, IHC, IP, Depletion, Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC, CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F, FC, 3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 3    Revision Date: 10-23-2018

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD8a

  • Biotin anti-mouse CD8a

  • FITC anti-mouse CD8a

  • PE anti-mouse CD8a

  • PE/Cyanine5 anti-mouse CD8a

  • Purified anti-mouse CD8a

  • PE/Cyanine7 anti-mouse CD8a

  • APC/Cyanine7 anti-mouse CD8a

  • Alexa Fluor® 488 anti-mouse CD8a

  • Alexa Fluor® 647 anti-mouse CD8a

  • Pacific Blue™ anti-mouse CD8a

  • Alexa Fluor® 700 anti-mouse CD8a

  • PerCP/Cyanine5.5 anti-mouse CD8a

  • PerCP anti-mouse CD8a

  • Brilliant Violet 421™ anti-mouse CD8a

  • Brilliant Violet 570™ anti-mouse CD8a

  • Brilliant Violet 650™ anti-mouse CD8a

  • Brilliant Violet 605™ anti-mouse CD8a

  • Ultra-LEAF™ Purified anti-mouse CD8a

  • Brilliant Violet 711™ anti-mouse CD8a

  • Brilliant Violet 785™ anti-mouse CD8a

  • Brilliant Violet 510™ anti-mouse CD8a

  • Purified anti-mouse CD8a (Maxpar® Ready)

  • Alexa Fluor® 594 anti-mouse CD8a

  • PE/Dazzle™ 594 anti-mouse CD8a

  • APC/Fire™ 750 anti-mouse CD8a

  • GoInVivo™ Purified anti-mouse CD8a

  • TotalSeq™-A0002 anti-mouse CD8a

  • Spark Blue™ 550 anti-mouse CD8a

  • Spark NIR™ 685 anti-mouse CD8a

  • TotalSeq™-C0002 anti-mouse CD8a

  • TotalSeq™-B0002 anti-mouse CD8a

  • Spark YG™ 570 anti-mouse CD8a

  • PE/Fire™ 640 anti-mouse CD8a

  • PE/Fire™ 700 anti-mouse CD8a

  • Spark Blue™ 574 anti-mouse CD8a Antibody

  • Spark Violet™ 423 anti-mouse CD8a Antibody

  • Spark UV™ 387 anti-mouse CD8a

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account